Literature DB >> 23545163

Progesterone blunts vascular endothelial cell secretion of endothelin-1 in response to placental ischemia.

Luissa V Kiprono1, Kedra Wallace, Janae Moseley, James Martin, Babbette Lamarca.   

Abstract

OBJECTIVE: Preeclampsia (PE) is associated with hypertension and elevated endothelin (ET-1), an indicator of endothelial cell activation and dysfunction. Reduction of uteroplacental perfusion (RUPP) in the pregnant rat model of PE is characterized by elevated mean arterial pressure, inflammatory cytokines, and activation of the ET-1 system. We aim to determine whether 17-alpha-hydroxyprogesterone caproate (17-OHPC) or progesterone suppresses these pathways. STUDY
DESIGN: Plasma progesterone was purified from normal pregnant (NP) and PE patients and measured via enzyme-linked immunosorbent assay. Human umbilical vein endothelial cells were exposed to the sera with or without progesterone added and ET-1 was measured. Pregnant rats underwent the RUPP procedure with or without intraperitoneal 17-OHPC. Mean arterial pressure was compared in RUPP vs NP rats. Human umbilical vein endothelial cells were exposed to NP or RUPP sera, with and without progesterone and ET-1 measured.
RESULTS: Progesterone was significantly decreased in PE women compared with NP women. In response to human sera, ET-1 was elevated in PE women compared to NP women, and decreased with addition of progesterone. Mean arterial pressure was significantly elevated in RUPP vs NP rats but was attenuated by 17-OHPC. ET-1 secretion was stimulated significantly by RUPP compared to NP rat sera, but attenuated by progesterone.
CONCLUSION: Circulating progesterone is significantly lower in PE women compared to controls. 17-OHPC attenuates hypertension in response to placental ischemia in RUPP rats. Progesterone blunts vascular ET-1 stimulated at cellular level by sera from PE women or RUPP rats. Decreased circulating progesterone is associated with stimulation of ET-1. 17-OHPC supplementation blunts hypertension and progesterone blunts endothelial cell ET-1 secretion in response to placental ischemia.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Keywords:  endothelin; placental ischemia; preeclampsia; progesterone

Mesh:

Substances:

Year:  2013        PMID: 23545163      PMCID: PMC4052216          DOI: 10.1016/j.ajog.2013.03.032

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  24 in total

1.  Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction.

Authors:  J P Granger; B T Alexander; M T Llinas; W A Bennett; R A Khalil
Journal:  Hypertension       Date:  2001-09       Impact factor: 10.190

2.  Progesterone therapy in pre-eclamptic toxaemia.

Authors:  M B Sammour; H El-Kabarity; A S Khalifa
Journal:  Acta Obstet Gynecol Scand       Date:  1975       Impact factor: 3.636

3.  Pregnancy hormones, pre-eclampsia, and implications for breast cancer risk in the offspring.

Authors:  Rulla Tamimi; Pagona Lagiou; Lars J Vatten; Lorelei Mucci; Dimitrios Trichopoulos; Susan Hellerstein; Anders Ekbom; Hans-Olov Adami; Chung-Cheng Hsieh
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-07       Impact factor: 4.254

4.  Early symptoms of pre-eclamptic toxaemia.

Authors:  K DALTON
Journal:  Lancet       Date:  1960-01-23       Impact factor: 79.321

Review 5.  The pathophysiology of preeclampsia involves altered levels of angiogenic factors promoted by hypoxia and autoantibody-mediated mechanisms.

Authors:  Estibalitz Laresgoiti-Servitje; Nardhy Gomez-Lopez
Journal:  Biol Reprod       Date:  2012-08-23       Impact factor: 4.285

Review 6.  Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy.

Authors:  James M Roberts; Gail Pearson; Jeff Cutler; Marshall Lindheimer
Journal:  Hypertension       Date:  2003-02-10       Impact factor: 10.190

7.  Expression of inflammatory cytokines in placentas from women with preeclampsia.

Authors:  D F Benyo; A Smarason; C W Redman; C Sims; K P Conrad
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

8.  Serum levels of progesterone in patients with preeclampsia.

Authors:  H Zeisler; M O Sator; E A Joura
Journal:  Wien Klin Wochenschr       Date:  2000-04-21       Impact factor: 1.704

9.  The myth of transient hypertension: descriptor or disease process?

Authors:  D A Terrone; B K Rinehart; W L May; R W Martin; J N Martin
Journal:  Am J Perinatol       Date:  2001       Impact factor: 1.862

Review 10.  Placental cytokines and the pathogenesis of preeclampsia.

Authors:  K P Conrad; D F Benyo
Journal:  Am J Reprod Immunol       Date:  1997-03       Impact factor: 3.886

View more
  20 in total

1.  17-hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model.

Authors:  Lorena M Amaral; Denise C Cornelius; Ashlyn Harmon; Janae Moseley; James N Martin; Babbette LaMarca
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

2.  Continued Investigation Into 17-OHPC: Results From the Preclinical RUPP Rat Model of Preeclampsia.

Authors:  Lorena M Amaral; Jessica L Faulkner; Jamil Elfarra; Denise C Cornelius; Mark W Cunningham; Tarek Ibrahim; Venkata Ramana Vaka; Jessica McKenzie; Babbette LaMarca
Journal:  Hypertension       Date:  2017-10-30       Impact factor: 10.190

Review 3.  The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia.

Authors:  Langeza Saleh; Koen Verdonk; Willy Visser; Anton H van den Meiracker; A H Jan Danser
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-01-10

4.  17-Hydroxyprogesterone caproate improves T cells and NK cells in response to placental ischemia; new mechanisms of action for an old drug.

Authors:  Jamil T Elfarra; Jesse N Cottrell; Denise C Cornelius; Mark W Cunningham; Jessica L Faulkner; Tarek Ibrahim; Babbette Lamarca; Lorena M Amaral
Journal:  Pregnancy Hypertens       Date:  2019-12-02       Impact factor: 2.899

5.  Progesterone supplementation attenuates hypertension and the autoantibody to the angiotensin II type I receptor in response to elevated interleukin-6 during pregnancy.

Authors:  Lorena M Amaral; Luissa Kiprono; Denise C Cornelius; Carrie Shoemaker; Kedra Wallace; Janae Moseley; Gerd Wallukat; James N Martin; Ralf Dechend; Babbette LaMarca
Journal:  Am J Obstet Gynecol       Date:  2014-02-15       Impact factor: 8.661

Review 6.  Identifying immune mechanisms mediating the hypertension during preeclampsia.

Authors:  Babbette LaMarca; Denise C Cornelius; Ashlyn C Harmon; Lorena M Amaral; Mark W Cunningham; Jessica L Faulkner; Kedra Wallace
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-04-20       Impact factor: 3.619

Review 7.  Role of the endothelin system in sexual dimorphism in cardiovascular and renal diseases.

Authors:  Eman Y Gohar; Fernanda R Giachini; David M Pollock; Rita C Tostes
Journal:  Life Sci       Date:  2016-03-03       Impact factor: 5.037

Review 8.  Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms.

Authors:  Frank T Spradley; Ana C Palei; Joey P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-10-07       Impact factor: 3.619

9.  Vitamin D supplementation improves pathophysiology in a rat model of preeclampsia.

Authors:  Jessica L Faulkner; Denise C Cornelius; Lorena M Amaral; Ashlyn C Harmon; Mark W Cunningham; Marie M Darby; Tarek Ibrahim; D'Andrea S Thomas; Florian Herse; Gerd Wallukat; Ralf Dechend; Babbette LaMarca
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-12-16       Impact factor: 3.619

Review 10.  Gestational Hypoxia and Developmental Plasticity.

Authors:  Charles A Ducsay; Ravi Goyal; William J Pearce; Sean Wilson; Xiang-Qun Hu; Lubo Zhang
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.